Table 1

Baseline characteristics of study population according to the starting antifibrotic therapy (pirfenidone or nintedanib)

Nintedanib (n=85)Pirfenidone (n=147)Total (n=232)P value
Age (years), mean (SD)69.0 (8.3)70.4 (7.7)69.9 (7.9)0.190*
Sex male, n (%)69 (81.2%)117 (79.6%)186 (80.2%)0.771†
Smoking history
 Current smoker, n (%)9 (10.6%)9 (6.1%)18 (7.8%)0.325†
 Pack years, mean (SD)31.8 (26.7)29.9 (27.7)30.6 (27.3)0.622*
BMI, mean (SD)28.9 (3.4)29.0 (4.1)28.9 (3.9)0.891*
Comorbidities
 Any, n (%)49 (57.6%)101 (68.7%)150 (64.7%)0.090†
 Charlson Comorbidity Index, mean (SD)3.6 (1.6)4.1 (1.7)3.9 (1.7)0.017*
 Respiratory comorbidities, n (%)30 (35.3%)50 (34.0%)80 (34.5%)0.843†
 Cardiovascular comorbidities, n (%)21 (24.7%)53 (36.1%)74 (31.9%)0.074†
 GORD, n (%)22.0 (26.2%)30.0 (20.4%)52.0 (22.5%)0.311†
 Type II DM, n (%)15.0 (17.6%)38.0 (25.9%)53.0 (22.8%)0.152†
 CKD, n (%)10.0 (11.8%)8.0 (5.4%)18.0 (7.8%)0.083†
 Depression, n (%)8.0 (9.4%)10.0 (6.8%)18.0 (7.8%)0.126†
Days since diagnosis, mean (SD)280.0 (698.3)260.3 (686.5)267.5 (689.4)0.834*
GAP index, n (%)0.729†
 Stage I25 (30.1%)43 (29.3%)68 (29.6%)
 Stage II43 (51.8%)71 (48.3%)114 (49.6%)
 Stage III15 (18.1%)33 (22.4%)48 (20.9%)
HRCT pattern, n (%)0.245†
 UIP pattern48 (57.1%)75 (51.4%)123 (53.5%)
 Probable UIP pattern27 (32.1%)55 (37.7%)82 (35.7%)
 Indeterminate UIP pattern8 (9.5%)15 (10.3%)23 (10.0%)
 Alternative pattern1 (1.2%)1 (0.7%)2 (0.9%)
Pulmonary function test
 FEV1 % predicted, mean (SD)85.2 (17.6)84.8 (15.3)85.0 (16.6)0.875*
 FVC % predicted, mean (SD)83.1 (20.6)79.7 (17.5)80.9 (18.7)0.174*
 DLCO % predicted, mean (SD)50.4 (17.7)50.5 (14.5)50.4 (15.7)0.979*
 6MWT m, mean (SD)447.7 (120.0)408.8 (119.4)422.9 (120.7)0.068*
 SpO2%, mean (SD)95.6 (2.6)95.6 (2.4)95.6 (2.5)0.848*
Medical therapy
 Oxygen therapy, n (%)26 (30.6%)61 (41.5%)87 (37.5%)0.098†
 Oral corticosteroids, n (%)16 (18.8%)32 (21.8%)48 (20.7%)0.594†
 PPI, n (%)69 (81.2%)120 (81.6%)189 (81.5%)0.931†
 Polypharmacy, n (%)25 (29.8%)65 (44.2%)90 (39.0%)0.030†
  • *Linear model analysis of variance.

  • †Pearson’s χ2 test.

  • BMI, body mass index; CKD, chronic kidney disease; DLCO, lung diffusion for carbon monoxide; DM, diabetes mellitus; FEV1, forced espiratory volume in the first second; FVC, forced vital capacity; GORD, gastro-oesophageal reflux disease; HRCT, high-resolution CT scan; GAP index, gender, age and pulmonary characteristics (reported in reference 6); 6MWT, 6 min walking test; PPI, proton pump inhibitor; SpO2, transcutaneous oxygen saturation; UIP, usual interstitial pneumonia.